Valneva and LimmaTech Biologics Join Forces to Develop Shigella4V Against Shigellosis
Shots:
- Valneva & LimmaTech have signed an exclusive licensing agreement to develop, manufacture & commercialize Shigella4V (S4V), a tetravalent bioconjugate vaccine, to prevent shigellosis
- As per the agreement, LimmaTech is entitled to receive ~$10.7M upfront, additional regulatory, development & sales-based milestones plus low double-digit royalties
- LimmaTech will carry out the P-II Controlled Human Infection Model (CHIM) and P-II trial in pediatrics across low & middle-income countries (LMICs) during H2’24. Valneva will handle further development, CMC, regulatory activities & commercialization across the globe
Ref: Valneva | Image: Valneva
Related News:- Valneva Reports EMA Acceptance of VLA1553 for Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
